Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Agilent Technologies Inc.. (10/26/16). "Press Release: Agilent Technologies Presents Thought Leader Award to Influential Cancer Researcher". Santa Clara, CA.

Products Product CRISPR gene editing technology
  Product 2 oncology
Persons Person Wadsworth-Hansen, Victoria (Agilent 201506 Director Global Business Public Relations)
  Person 2 Verrelst, Herman (Biocartis 201709– CEO before Agilent + Cartagenia + Medicim + Data4s)

Biologist Scott Lowe Recognized for Contributions to Next-Generation Tools

Agilent Technologies Inc. (NYSE: A) today announced that Dr. Scott Lowe has received an Agilent Thought Leader Award in recognition for his contributions to the identification of key genes — including those that promote or suppress cancer — and their characterization as therapeutic targets using novel genetic screens and animal models.

Dr. Lowe chairs the Cancer Biology & Genetics Program at the Sloan Kettering Institute as well as the Geoffrey Beene Cancer Research Center at the Memorial Sloan Kettering Cancer Center and is widely recognized for his work in cancer biology.

The award will support Dr. Lowe's work on the development and implementation of next generation CRISPR-based genetic screens to systematically identify and characterize novel targets for cancer therapeutics. Notably, Agilent will support the work in Dr. Lowe's laboratory by providing unique capabilities for the generation of CRISPR libraries, including their massively parallel oligonucleotide synthesis technologies and other molecular biology tools and reagents.

"We anticipate the work by Dr. Lowe will not only generate new CRISPR-based technologies and resources for identifying therapeutic targets, but will also serve as an example for others to create equivalent tools for other diseases," said Herman Verrelst, Agilent vice president & general manager, Genomics Solutions Division and Clinical Applications Division, and the executive sponsor of this award. "We are pleased to support Dr. Lowe's research as it promises to have many applications in identification and validation of cancer drug targets and in creating effective pharmaceuticals."

"I am honored and pleased to receive the Thought Leader Award from Agilent," said Dr. Lowe. "This award represents a unique partnership that will enable us to rapidly develop and implement genome engineering technologies to identify strategies for treating cancers that are currently resistant to conventional therapies."

The Agilent Thought Leader Award promotes fundamental scientific advances by contributing financial support, products and expertise to the research of influential thought leaders in the life sciences, diagnostics and applied chemical markets. Information about previous award recipients is available at Agilent's Thought Leader website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at

# # #

For images related to this press release,
please visit the ImageLibrary (Images 2016-16)
Dr. Scott Lowe - Agilent Thought Leader 2016


Victoria Wadsworth-Hansen
Agilent Technologies
+1 408-553-2005

Record changed: 2016-11-04


Picture [iito] No Tracking 650x80px

More documents for Agilent (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top